SomnoMed Limited (SOMNF) Q4 2026 Earnings Call August 27, 2026 8:30 PM EDT
Company Participants
Karen Borg – CEO & Executive Director
Ye-Fei Guo – Chief Financial Officer
Conference Call Participants
Jane Lowe
Presentation
Jane Lowe
Well, good morning, everyone, and welcome to SomnoMed’s results presentation for the FY ’26 full year. My name is Jane Lowe, and I will be your moderator for today’s session. With me today are Karen Borg, who is CEO; and Ye-Fei Guo, who is CFO of SomnoMed. They will take us through the results presentation, which was lodged with the ASX this morning.
A bit of housekeeping before we kick off. Today’s webinar is being recorded, including the Q&A, and we will post this on SomnoMed’s website following the completion of the webinar. We will invite you to ask questions at the end of the presentation. [Operator Instructions].
For now though, I’ll pass over to Karen to kick off the presentation. Thank you, Karen.
Karen Borg
CEO & Executive Director
Great. Thanks, Jane. Before we begin, I’d like to draw your attention to the disclaimer on the screen. Today’s presentation contains forward-looking statements, which involve risks and uncertainties. Actual results may differ from those anticipated, and investors should not place undue reliance on these statements.
So now let’s have a look at the company highlights. Looking at these dynamics around the SomnoMed business, and then we’ll look at our financial and operating highlights. Now SomnoMed’s vision is a world where oral appliance therapy is the standard of care for obstructive sleep apnea treatment, or OSA. Our mission is to set the standard for outcomes, innovation and patient experience while helping drive the transformation of sleep medicine worldwide.
The market opportunity remains vast. Approximately 1 billion people globally suffer from obstructive sleep apnea, which presents a